Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

D.Western Therapeutics Institute (6DW) AI Stock Analysis

0 Followers
DE:6DW

D.Western Therapeutics Institute

(Frankfurt:6DW)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross MarginsVery strong gross margins indicate that successful products or development-related revenue can retain substantial value after direct costs. If revenue stabilizes and operating spending is controlled, this margin structure could provide meaningful operating leverage and support eventual profitability.
Negative Factors
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not currently self-funding its operations. Even though the burn improved materially in 2025, continued cash consumption can require additional financing and may constrain investment in drug discovery and development.

D.Western Therapeutics Institute (6DW) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:6DW-51.32%EWG+7.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 18.23M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-4.1
Beta (1Y)
-0.49
Revenue Growth
-45.81%
EPS Growth
59.30%
Country
Germany
Employees
19
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

D.Western Therapeutics Institute Business Overview & Revenue Model

Company Description

D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...

D.Western Therapeutics Institute Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6DW against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4593JP:459348NeutralJPY 34.43B45.77――-47.32%―
JP:4978JP:497844NeutralJPY 12.39B-22.88――-18.71%-246.54%
JP:4599JP:459938UnderperformJPY 8.15B-3.77―――4.85%
JP:4592JP:459229UnderperformJPY 69.00B-16.85-37.79%――5.71%
JP:7776JP:777626UnderperformJPY 7.18B-5.52――-56.16%3.12%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%DE:6DWJP:4592JP:4593JP:4599JP:4978JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:6DW and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6DWD.Western Therapeutics Institute, Inc.0.26-0.27-50.86%
JP:4592SanBio Co 848.00-1625.00-65.71%
JP:4593Healios KK245.00-222.00-47.54%
JP:4599StemRIM Inc.123.00-150.00-54.95%
JP:4978ReproCELL Inc.113.00-55.00-32.74%
JP:7776CellSeed Inc.172.00-251.00-59.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.